Drugs / QLS5316
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07358884 | Jan 2026 → Dec 2027 expected | colorectal cancer, gastroesophageal adenocarcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS5316 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07358884 ↗ |